Skip to main content

Biotalys lifts EVOCA NG production efficiency more than 15-fold in pilot campaign

Biotalys completed a five batch pilot campaign with 21st.BIO for biofungicide EVOCA NG and reports a more than 15-fold gain in production efficiency.

Biotalys lifts EVOCA NG production efficiency more than 15-fold in pilot campaign

Biotalys NV (Euronext: BTLS), the Ghent biocontrol developer spun out of the Flanders Institute for Biotechnology in 2013, said on 9 November 2026 that it had completed a pilot production campaign for EVOCA NG, the first commercial product candidate from its AGROBODY protein platform. The campaign was run with 21st.BIO, a precision fermentation technology provider with offices in Soborg, Denmark, and Davis, California. It covered five consecutive production batches, tested consistency and scalability, and delivered what Biotalys describes as a more than 15-fold improvement in production efficiency compared with EVOCA, its first generation product.

EVOCA NG is a protein-based biofungicide aimed at Botrytis, or grey mould, and powdery mildew in fruit and vegetables. Biotalys plans registration in the United States and the European Union in 2029 and puts the combined market for the two regions at about 1.1 billion dollars, citing Kynetec data from 2020 alongside its own estimates. The batch data is intended to feed the regulatory studies that registration requires, and the company says the next step is scaling production with contract manufacturing organisations.

The regulatory position is unusual for a product this early. EVOCA NG carries the same bioactive ingredient as EVOCA, which the US Environmental Protection Agency approved in December 2025 and which picked up state approvals in Florida and California during 2026. The European review of EVOCA is still running, with the European Food Safety Authority expected to conclude by the end of 2026 or in early 2027 after a recent submission of additional data. On that basis Biotalys expects a significantly shorter regulatory path for EVOCA NG, through equivalency or amendment procedures rather than a full new dossier.

“This is a key milestone in the transition of EVOCA NG from development to commercialisation,” said chief executive Carlo Boutton, who was appointed permanent CEO in August 2026 after running the company on an interim basis from March. The result lands on the schedule the company gave in its half-year report of 20 August 2026, which said the five batch campaign had begun in early August with an outcome expected by early November. That same report set out the constraint around it: 11.9 million euros of cash at 30 June 2026 against 15.7 million a year earlier, an operating loss of 9.1 million euros for the half, and a cash runway reaching only to the end of the first quarter of 2027.

Why it matters for AgTech founders: a biological that performs in the trial and cannot be manufactured at a price growers will pay is not yet a product, and this release moves the number that decides which of the two it is. A more than 15-fold efficiency gain is a cost of goods result before it is a science result, and it came from a fermentation partner rather than from owned capacity, which is the only sensible route for a company with 11.9 million euros in the bank. Two things travel from this to anyone building a protein-based input. First, put titre and yield on the milestone plan next to efficacy, because registration dossiers and offtake negotiations both price off cost per hectare. Second, look hard at the distance between a 2029 registration and a runway ending in early 2027. That gap gets closed with manufacturing and distribution partners, not with patience, and a verified production milestone is precisely the evidence that makes such a partner move. That is why it was published now rather than saved for the annual report.

Source: GlobeNewswire

Biotalys lifts EVOCA NG production efficiency more than 15-fold in pilot campaign

Five consecutive batches run with precision fermentation specialist 21st.BIO clear the way for the registration studies behind the Ghent company's first commercial biofungicide.

By Dirk Vandenhirtz

· Biologicals · Europe · 4 min

Biotalys NV (Euronext: BTLS), the Ghent biocontrol developer spun out of the Flanders Institute for Biotechnology in 2013, said on 9 November 2026 that it had completed a pilot production campaign for EVOCA NG, the first commercial product candidate from its AGROBODY protein platform. The campaign was run with 21st.BIO, a precision fermentation technology provider with offices in Soborg, Denmark, and Davis, California. It covered five consecutive production batches, tested consistency and scalability, and delivered what Biotalys describes as a more than 15-fold improvement in production efficiency compared with EVOCA, its first generation product.

EVOCA NG is a protein-based biofungicide aimed at Botrytis, or grey mould, and powdery mildew in fruit and vegetables. Biotalys plans registration in the United States and the European Union in 2029 and puts the combined market for the two regions at about 1.1 billion dollars, citing Kynetec data from 2020 alongside its own estimates. The batch data is intended to feed the regulatory studies that registration requires, and the company says the next step is scaling production with contract manufacturing organisations.

The regulatory position is unusual for a product this early. EVOCA NG carries the same bioactive ingredient as EVOCA, which the US Environmental Protection Agency approved in December 2025 and which picked up state approvals in Florida and California during 2026. The European review of EVOCA is still running, with the European Food Safety Authority expected to conclude by the end of 2026 or in early 2027 after a recent submission of additional data. On that basis Biotalys expects a significantly shorter regulatory path for EVOCA NG, through equivalency or amendment procedures rather than a full new dossier.

“This is a key milestone in the transition of EVOCA NG from development to commercialisation,” said chief executive Carlo Boutton, who was appointed permanent CEO in August 2026 after running the company on an interim basis from March. The result lands on the schedule the company gave in its half-year report of 20 August 2026, which said the five batch campaign had begun in early August with an outcome expected by early November. That same report set out the constraint around it: 11.9 million euros of cash at 30 June 2026 against 15.7 million a year earlier, an operating loss of 9.1 million euros for the half, and a cash runway reaching only to the end of the first quarter of 2027.

Why it matters for AgTech founders: a biological that performs in the trial and cannot be manufactured at a price growers will pay is not yet a product, and this release moves the number that decides which of the two it is. A more than 15-fold efficiency gain is a cost of goods result before it is a science result, and it came from a fermentation partner rather than from owned capacity, which is the only sensible route for a company with 11.9 million euros in the bank. Two things travel from this to anyone building a protein-based input. First, put titre and yield on the milestone plan next to efficacy, because registration dossiers and offtake negotiations both price off cost per hectare. Second, look hard at the distance between a 2029 registration and a runway ending in early 2027. That gap gets closed with manufacturing and distribution partners, not with patience, and a verified production milestone is precisely the evidence that makes such a partner move. That is why it was published now rather than saved for the annual report.

Source: GlobeNewswire

Back to AgTech News